Date of Abstract presentation11th December 2023IndicationsMultiple MyelomaAbstract Number1021Abstract typeOral
CARVYKTI (ciltacabtagene autoleucel) is a B-cell maturation antigen (BCMA)-directed, genetically modified autologous T-cell immunotherapy, which involves reprogramming a patient’s T cells with a transgene encoding a chimeric antigen receptor (CAR) that identifies and eliminates cells that express BCMA. The data presented from the CARTITUDE-2 trial cohorts A and B, at the ASH 2023 conference revealed that, with a median follow-up of approximately 29 months, patients, including those with lenalidomide-refractory multiple myeloma after one to three lines of t...